WO 2005/107384 PCT/US2005/010935

CLAIMS

What is claimed is:

5

10

15

20

25

1. A method for treating a blood disorder; treating sickle cell anemia; or treating thalassemia in a patient in need thereof comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.

- 2. The method of claim 1, further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
- 3. The method of claim 1, wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
- 4. The method of claim 2, wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
- 5. The method of claim 4, wherein the hydralazine compound is hydralazine hydrochloride.
- 6. A method for treating pulmonary hypterension in a patient with sickle cell anemia comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.
- 7. The method of claim 6, further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
- 8. The method of claim 6, wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
- 9. The method of claim 7, wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
- 10. The method of claim 9, wherein the hydralazine compound is hydralazine hydrochloride.
- 11. A method for treating pulmonary hypterension in a patient with thalassemia comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.
 - 12. The method of claim 11, further comprising administering a

WO 2005/107384 PCT/US2005/010935

therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.

- 13. The method of claim 11, wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
- 14. The method of claim 12, wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
- 15. The method of claim 14, wherein the hydralazine compound is hydralazine hydrochloride.
- 16. A method for treating systemic systolic hypertension, oxidative stress and/or endothelial dysfunction in patient with sickle cell anemia and/or thalassemia by administering a therapeutically effective amount of at least one nitric oxide donor compound.
 - 17. The method of claim 16, further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
 - 18. The method of claim 16, wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
 - 19. The method of claim 17, wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
 - 20. The method of claim 19, wherein the hydralazine compound is hydralazine hydrochloride.

15

20

5